HUTCHMED (China) Limited (NASDAQ:HCM) is forecast to post earnings of $0.06 per share in fiscal 2025

HUTCHMED (China) Limited (NASDAQ:HCM – Free Report ) – Stock analysts at Trinity Delta upped their FY2025 EPS estimates for HUTCHMED in a note issued to investors on Wednesday, September 25th. Trinity Delta analyst L. Gregorek now anticipates that the company will earn $0.06 per share for the year, up from their prior estimate of $0.05. The consensus estimate for HUTCHMED’s current full year earnings is ($0.33) per share.

HCM has been the subject of a number of other research reports. StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Thursday, July 18th. Goldman Sachs Group upped their price objective on shares of HUTCHMED from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st.

View the latest inventory report on HCM

HUTCHMED trading up 2.6%

Shares of HCM stock opened at $19.53 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68, and a current ratio of 2.81. HUTCHMED has a fifty-two week low of $11.93 and a fifty-two week high of $21.92. The company’s 50-day simple moving average is $18.05, and its two-hundred-day simple moving average is $18.13.

Institutional investors intervene on HUTCHMED

A number of institutional investors have recently made changes to their positions in the company. Rhumbline Advisers raised its position in HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after buying an additional 564 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in HUTCHMED by 9.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock worth $226,000 after acquiring an additional 1,168 shares during the period. Hennion & Walsh Asset Management Inc. grew its position in shares of HUTCHMED by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 57,010 shares of the company’s stock valued at $958,000 after purchasing an additional 1,388 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of HUTCHMED by 65.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,933 shares of the company’s stock valued at $100,000 after buying an additional 2,340 shares during the period. Finally, Russell Investments Group Ltd. grew its position in shares of HUTCHMED by 70.5% in the first quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company’s stock valued at $304,000 after purchasing an additional 7,515 shares during the period. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

(Get a free report)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops and commercializes targeted therapies and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company is developing Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC) and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, stable endometrial cancer microsatellite-CRC (EMC), NSCLC, RCC, gastrointestinal, cervical and solid tumors.

Featured stories

Get news and ratings for HUTCHMED daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HUTCHMED and related companies with MarketBeat.com ‘s FREE daily email newsletter.